Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling. The post Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals appeared first on Investor’s Business Daily.
Wall Street projects the company turning a net profit of 12 cents a share this year. The post Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look appeared first on Investor’s Business Daily.
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. The post The Surprise That Sent Vertex — And Its Chief Rival — Soaring appeared first on Investor’s…
Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren’s treatment. The post Amgen Boasts Success In Sjogren’s; Shares Charge Ahead appeared first on Investor’s Business Daily.
Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell. The post Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. appeared first on Investor’s Business Daily.
Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts. The post Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash appeared first on Investor’s Business Daily.
Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD. The post How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won appeared first on Investor’s Business Daily.
Incyte is Friday’s IBD Stock Of The Day. Shares are testing a trendline within a base. That would offer an early entry into the biotech.. The post IBD Stock Of The Day Eyes Buy Points As Investors Dig Into Its…
Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. The post The Biotech Surged 50% On Positive Data In March. Now, It’s Almost Gone.…
Ultragenyx Pharmaceuticals won approval for its newest gene therapy on Thursday, helping shares partially reverse a catastrophic dive. The post How This Gene Therapy Name Partially Reversed Its Catastrophic 44% Dive appeared first on Investor’s Business Daily.
